Jeff Yass’s Nuvectis Pharma NVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-25,100
Closed -$462K – 14230
2026
Q2
$462K Buy
+25,100
New +$281K ﹤0.01% 10091
2026
Q1
– Sell
-60,600
Closed -$458K – 13828
2025
Q4
$458K Buy
+60,600
New +$395K ﹤0.01% 9003
2025
Q3
– Sell
-50,100
Closed -$374K – 13438
2025
Q2
$374K Sell
50,100
-26,300
-34% -$238K ﹤0.01% 9846
2025
Q1
$746K Buy
+76,400
New +$550K ﹤0.01% 7993

Other funds holding NVCT

Jeff Yass's NVCT Position: Q3 2026 in Review

Jeff Yass reduced its Nuvectis Pharma (NVCT) stake by 33% in Q3 2026, selling an estimated $1.52M and leaving 145,121 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #5375.

Jeff Yass first reported a position in NVCT in Q4 2023 and has held it in 9 quarters since. The position peaked at $4M in Q2 2026. 95 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • Jeff Yass held 145,121 shares of Nuvectis Pharma worth $3.06M as of Q3 2026.
  • Jeff Yass sold 72,165 Nuvectis Pharma shares in Q3 2026, an estimated $1.52M.
  • Nuvectis Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #5375 holding.
  • Jeff Yass first reported a position in Nuvectis Pharma in Q4 2023 and has held it in 9 quarters since.
  • Jeff Yass's Nuvectis Pharma position peaked at $4M in Q2 2026.
  • 95 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.